Last update: Oct. 19, 2014

Dexlansoprazole

Very Low Risk for breastfeeding


Safe. Compatible.
Minimal risk for breastfeeding and infant.

R Isomer of Lansoprazole with similar pharmacokinetics.

At latest update, relevant information on excretion into breast milk was not found.

Due to a high serum-protein-binding capacity, excretion of Lansoprazole into breast milk is non-significant.

Since it's neutralized by the acid pH of stomach, capsules with enteric coated granules are used. Because of this, it is thought that the small quantity of Lansoprazole that may reach the breast milk would be neutralized by infant's stomach. In addition, absorption is greatly decreased by the presence of food.

Both Omeprazole and Pantoprazole pertain to the same chemical group with similar pharmacokinetics that are excreted in non-significant amount into the breast milk.

Medication that has been used for treatment of newborn and premature infants.

Hyperprolactinemia and galactorrhea have been reported by the use of such medication, though some authors have failed to show the same findings.

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Tradenames

Main tradenames from several countries containing Dexlansoprazole in its composition:

Pharmacokinetics

Variable Value Unit
Molecular weight 369 daltons
Protein Binding 96 - 99 %
VD 0,6 l/Kg
Tmax 1 - 5 hours
T1/2 1 - 2 hours

References

  1. PDR.net. Dexlansoprazole. Drug Summary. 2014 Full text (in our servers)
  2. Jabbar A, Khan R, Farrukh SN. Hyperprolactinaemia induced by proton pump inhibitor. J Pak Med Assoc. 2010 Abstract
  3. Dexlansoprazol. Ficha técnica. 2010 Full text (in our servers)
  4. Olsen KM, Hitzeman ML. Dexlansoprazole MR in the Management of Gastroesophageal Reflux Disease Clinical Medicine: Therapeutics 2009:1 1641–1652. 2009 Full text (in our servers)
  5. Izquierdo Prieto OM, Moreno Alía E, Rosillo González A. [Galactorrhea induced by lansoprazole]. Aten Primaria. 2004 Abstract
  6. Dammann HG, von zur Mühlen A, Balks HJ, Damaschke A, Steinhoff J, Hennig U, Schwarz JA, Fuchs W. The effects of lansoprazole, 30 or 60 mg daily, on intragastric pH and on endocrine function in healthy volunteers. Aliment Pharmacol Ther. 1993 Abstract

Total visits

6,619

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by AELAMA

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM